Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

29 Sept 2020

Abstract excerpt

IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 because of structural constraints in binding the RBD (mode A). However, a small subset of IGHV3-53 antibodies to the RBD contain a longer CDR H3. Crystal structures of two IGHV3-53 neutralizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Polyomavirus and related diseases
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33027617
DOI: 10.1016/j.celrep.2020.108274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding DomainPMID 33027617Read ↗

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

Structural basis of a public antibody response to SARS-CoV-2Semantic proximity Read ↗

Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patientsSemantic proximity Read ↗

Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody ResponsesSemantic proximity Read ↗

Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2Semantic proximity Read ↗

Structural and mutational analyses define distinct molecular routes to broad SARS-CoV-2 receptor-binding domain recognitionSemantic proximity Read ↗

Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responsesSemantic proximity Read ↗

Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variantsSemantic proximity Read ↗

An allelic atlas of immunoglobulin heavy chain variable regions reveals antibody binding epitope preference resilient to SARS-CoV-2 mutation escape.Semantic proximity Read ↗

Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responsesSemantic proximity Read ↗

The antigenic anatomy of SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.